Clinical significance of pharmacogenomic studies in tardive dyskinesia associated with patients with psychiatric disorders

References

• EvansWERellingMVPharmacogenomics: translating functional genomics into rational therapeuticsScience1999286543948749110521338
   PubMed Web of Science ®Google Scholar
• NewmanWGPayneKTrickerKTARGET study recruitment teamA pragmatic randomized controlled trial of thiopurine methyltransferase genotyping prior to azathioprine treatment: the TARGET studyPharmacogenomics201112681582621692613
   PubMed Web of Science ®Google Scholar
• GardosGCaseyDEColeJOTen-year outcome of tardive dyskinesiaAm J Psychiatry199415168368417910437
   PubMed Web of Science ®Google Scholar
• LeoRJMovement disorders associated with the serotonin selective reuptake inhibitorsJ Clin Psychiatry199657104494548909330
   PubMed Web of Science ®Google Scholar
• JankovicJTardive syndromes and other drug-induced movement disordersClin Neuropharmacol19951831972148635179
   PubMed Web of Science ®Google Scholar
• ChiuHShumPLauJLamLLeeSPrevalence of tardive dyskinesia, tardive dystonia, and respiratory dyskinesia among Chinese psychiatric patients in Hong KongAm J Psychiatry19921498108110851353316
   PubMed Web of Science ®Google Scholar
• SramekJRoySAhrensTPinanongPCutlerNRPiEPrevalence of tardive dyskinesia among three ethnic groups of chronic psychiatric patientsHosp Community Psychiatry19914265905921677921
   PubMedGoogle Scholar
• van HartenPNMatroosGEHoekHWKahnRSThe prevalence of tardive dystonia, tardive dyskinesia, parkinsonism and akathisia The Curacao Extrapyramidal Syndromes Study: ISchizophr Res1996192–31952038789918
   PubMed Web of Science ®Google Scholar
• BaldessariniRJClinical and epidemiologic aspects of tardive dyskinesiaJ Clin Psychiatry1985464 Pt 28132858483
   PubMed Web of Science ®Google Scholar
• XiangYTWangCYSiTMTardive dyskinesia in the treatment of schizophrenia: the findings of the Research on Asian Psychotropic Prescription Pattern (REAP) survey (2001 – 2009)Int J Clin Pharmacol Ther201149638238721612745
   PubMed Web of Science ®Google Scholar
• SwartzJRBurgoyneKSmithMGadasallyRAnanthJAnanthKTardive dyskinesia and ethnicity: review of the literatureAnn Clin Psychiatry19979153599167836
   PubMedGoogle Scholar
• WonodiIAdamiHMCassadySLSherrJDAvilaMTThakerGKEthnicity and the course of tardive dyskinesia in outpatients presenting to the motor disorders clinic at the Maryland psychiatric research centerJ Clin Psychopharmacol200424659259815538119
   PubMed Web of Science ®Google Scholar
• EasthamJHLacroJPJesteDVEthnicity and movement disordersMt Sinai J Med1996635–63143198898534
   PubMedGoogle Scholar
• YassaRAnanthJFamilial tardive dyskinesiaAm J Psychiatry198113812161816196118067
   PubMed Web of Science ®Google Scholar
• WeinholdPWegnerJTKaneJMFamilial occurrence of tardive dyskinesiaJ Clin Psychiatry19814241651666110655
   PubMed Web of Science ®Google Scholar
• MüllerDJSchulzeTGKnappMFamilial occurrence of tardive dyskinesiaActa Psychiatr Scand2001104537537911722319
   PubMed Web of Science ®Google Scholar
• KapitanyTMeszarosKLenzingerEGenetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophreniaSchizophr Res19983221011069713905
   PubMed Web of Science ®Google Scholar
• FleemanNDundarYDicksonRCytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analysesPharmacogenomics J201111111420877299
   PubMed Web of Science ®Google Scholar
• ChenCHWeiFCKoongFJHsiaoKJAssociation of TaqI A polymorphism of dopamine D2 receptor gene and tardive dyskinesia in schizophreniaBiol Psychiatry19974178278299084902
   PubMed Web of Science ®Google Scholar
• SteenVMLovlieRMacEwanTMcCreadieRGDopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patientsMol Psychiatry1997221391459106238
   PubMed Web of Science ®Google Scholar
• SegmanRNeemanTHeresco-LevyUGenotypic association between the dopamine D3 receptor and tardive dyskinesia in chronic schizophreniaMol Psychiatry19994324725310395214
   PubMed Web of Science ®Google Scholar
• GaliliRMosbergGil-AdIWeizmanAMelamedEOffenDHaloperidol-induced neurotoxicity – possible implications for tardive dyskinesiaJ Neural Transm2000107447949011215758
   PubMed Web of Science ®Google Scholar
• PostAHolsboerFBehlCInduction of NF-kappaB activity during haloperidol-induced oxidative toxicity in clonal hippocampal cells: suppression of NF-kappaB and neuroprotection by antioxidantsJ Neurosci19981820823682469763469
   PubMed Web of Science ®Google Scholar
• BehlCRupprechtRSkutellaTHolsboerFHaloperidol-induced cell death – mechanism and protection with vitamin E in vitroNeuroreport1995713603648742488
   PubMed Web of Science ®Google Scholar
• ElkashefAMWyattRJTardive dyskinesia: possible involvement of free radicals and treatment with vitamin ESchizophr Bull199925473174010667743
   PubMed Web of Science ®Google Scholar
• SaizPASusceMTClarkDAAn investigation of the alpha1A-adrenergic receptor gene and antipsychotic-induced side-effectsHum Psychopharmacol200823210711417972277
   PubMed Web of Science ®Google Scholar
• LiouYJChenMLWangYCAnalysis of genetic variations in the RGS9 gene and antipsychotic-induced tardive dyskinesia in schizophreniaAm J Med Genet B Neuropsychiatr Genet2009150B223924218548510
   PubMed Web of Science ®Google Scholar
• ZaiCCTiwariAKMazzocoMAssociation study of the vesicular monoamine transporter gene SLC18A2 with tardive dyskinesiaJ Psychiatr Res201347111760176524018103
   PubMed Web of Science ®Google Scholar
• TiwariAKDeshpandeSNLererBNimgaonkarVLThelmaBKGenetic susceptibility to Tardive Dyskinesia in chronic schizophrenia subjects: V. Association of CYP1A2 1545 C>T polymorphismPharmacogenomics J20077530531116969362
   PubMed Web of Science ®Google Scholar
• TiwariAKZaiCCLikhodiOAssociation study of cannabinoid receptor 1 (CNR1) gene in tardive dyskinesiaPharmacogenomics J201212326026621266946
   PubMed Web of Science ®Google Scholar
• LiouYJWangYCChenJYThe coding-synonymous polymorphism rs1045280 (Ser280Ser) in beta-arrestin 2 (ARRB2) gene is associated with tardive dyskinesia in Chinese patients with schizophreniaEur J Neurol200815121406140819049562
   PubMed Web of Science ®Google Scholar
• BakkerPRvan HartenPNvan OsJAntipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactionsMol Psychiatry200813554455618180754
   PubMed Web of Science ®Google Scholar
• LiouYJLaiICLinMWHaplotype analysis of endothelial nitric oxide synthase (NOS3) genetic variants and tardive dyskinesia in patients with schizophreniaPharmacogenet Genomics200616315115716495774
   PubMed Web of Science ®Google Scholar
• DeshpandeSNVarmaPGSemwalPII. Serotonin receptor gene polymorphisms and their association with tardive dyskinesia among schizophrenia patients from North IndiaPsychiatr Genet200515315715816094246
   PubMed Web of Science ®Google Scholar
• CascorbiIPharmacogenetics of cytochrome p4502D6: genetic background and clinical implicationEur J Clin Invest200333Suppl 2172214641552
   PubMed Web of Science ®Google Scholar
• BertilssonLDahlMLDalenPAl-ShurbajiAMolecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugsBr J Clin Pharmacol200253211112211851634
   PubMed Web of Science ®Google Scholar
• ChidaMYokoiTNemotoNInabaMKinoshitaMKamatakiTA new variant CYP2D6 allele (CYP2D6*21) with a single base insertion in exon 5 in a Japanese population associated with a poor metabolizer phenotypePharmacogenetics19999328729310471060
   PubMedGoogle Scholar
• LeeSYSohnKMRyuJYYoonYRShinJGKimJWSequence-based CYP2D6 genotyping in the Korean populationTher Drug Monit200628338238716778723
   PubMed Web of Science ®Google Scholar
• LlerenaADahlMLEkqvistBBertilssonLHaloperidol disposition is dependent on the debrisoquine hydroxylation phenotype: increased plasma levels of the reduced metabolite in poor metabolizersTher Drug Monit19921432612641412613
   PubMed Web of Science ®Google Scholar
• PanLVander SticheleRRosseelMTBerloJADe SchepperNBelpaireFMEffects of smoking, CYP2D6 genotype, and concomitant drug intake on the steady state plasma concentrations of haloperidol and reduced haloperidol in schizophrenic inpatientsTher Drug Monit199921548949710519444
   PubMed Web of Science ®Google Scholar
• Yasui-FurukoriNKondoTSuzukiAEffect of the CYP2D6 genotype on prolactin concentration in schizophrenic patients treated with haloperidolSchizophr Res2001521–213914211595402
   PubMed Web of Science ®Google Scholar
• BrockmollerJKirchheinerJSchmiderJThe impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatmentClin Pharmacol Ther200272443845212386646
   PubMed Web of Science ®Google Scholar
• DesaiMTanus-SantosJELiLPharmacokinetics and QT interval pharmacodynamics of oral haloperidol in poor and extensive metabolizers of CYP2D6Pharmacogenomics J20033210511312746736
   PubMed Web of Science ®Google Scholar
• LlerenaABereczRDoradoPde la RubiaAQTc interval, CYP2D6 and CYP2C9 genotypes and risperidone plasma concentrationsJ Psychopharmacol200418218919315260906
   PubMed Web of Science ®Google Scholar
• ALLde la RubiaABereczRDoradoPRelationship between haloperidol plasma concentration, debrisoquine metabolic ratio, CYP2D6 and CYP2C9 genotypes in psychiatric patientsPharmacopsychiatry2004372697315048614
   PubMed Web of Science ®Google Scholar
• PanagiotidisGArthurHWLindhJDDahlMLSjöqvistFDepot haloperidol treatment in outpatients with schizophrenia on monotherapy: impact of CYP2D6 polymorphism on pharmacokinetics and treatment outcomeTher Drug Monit200729441742217667795
   PubMed Web of Science ®Google Scholar
• InadaTSenooHIijimaYYamauchiTYagiGCytochrome P450 II D6 gene polymorphisms and the neuroleptic-induced extrapyramidal symptoms in Japanese schizophrenic patientsPsychiatr Genet200313316316812960748
   PubMed Web of Science ®Google Scholar
• HendsetMHermannMLundeHRefsumHMoldenEImpact of the CYP2D6 genotype on steady-state serum concentrations of aripiprazole and dehydroaripiprazoleEur J Clin Pharmacol200763121147115117828532
   PubMed Web of Science ®Google Scholar
• SwenJJNijenhuisMde BoerAPharmacogenetics: from bench to byte – an update of guidelinesClin Pharmacol Ther201189566267321412232
   PubMed Web of Science ®Google Scholar
• KohnkeMDGrieseEUStosserDGaertnerIBarthGCytochrome P450 2D6 deficiency and its clinical relevance in a patient treated with risperidonePharmacopsychiatry200235311611812107857
   PubMed Web of Science ®Google Scholar
• JerlingMDahlMLAberg-WistedtAThe CYP2D6 genotype predicts the oral clearance of the neuroleptic agents perphenazine and zuclopenthixolClin Pharmacol Ther19965944234288612387
   PubMed Web of Science ®Google Scholar
• LinnetKWiborgOInfluence of Cyp2D6 genetic polymorphism on ratios of steady-state serum concentration to dose of the neuroleptic zuclopenthixolTher Drug Monit19961866296348946657
   PubMed Web of Science ®Google Scholar
• JaansonPMarandiTKiivetRAMaintenance therapy with zuclopenthixol decanoate: associations between plasma concentrations, neurological side effects and CYP2D6 genotypePsychopharmacology (Berl)20021621677312107620
   PubMed Web of Science ®Google Scholar
• DahlMLEkqvistBWidénJBertilssonLDisposition of the neuroleptic zuclopenthixol cosegregates with the polymorphic hydroxylation of debrisoquine in humansActa Psychiatr Scand1991841991021927573
   PubMed Web of Science ®Google Scholar
• Dahl-PuustinenMLLidénAAlmCNordinCBertilssonLDisposition of perphenazine is related to polymorphic debrisoquin hydroxylation in human beingsClinical Pharmacology and Therapeutics198946178812743709
   PubMed Web of Science ®Google Scholar
• OzdemirVBertilssonLMiuraJCYP2D6 genotype in relation to perphenazine concentration and pituitary pharmacodynamic tissue sensitivity in Asians: CYP2D6-serotonin-dopamine crosstalk revisitedPharmacogenet Genomics200717533934717429316
   PubMed Web of Science ®Google Scholar
• EapCBGuentertTWSchãublin-LoidlMPlasma levels of the enantiomers of thioridazine, thioridazine 2-sulfoxide, thioridazine 2-sulfone, and thioridazine 5-sulfoxide in poor and extensive metabolizers of dextromethorphan and mephenytoinClin Pharmacol Ther19965933223318653995
   PubMed Web of Science ®Google Scholar
• BereczRde la RubiaADoradoPThioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotypeEur J Clin Pharmacol2003591455012682803
   PubMed Web of Science ®Google Scholar
• WójcikowskiJMaurelPDanielWACharacterization of human cytochrome p450 enzymes involved in the metabolism of the piperidine-type phenothiazine neuroleptic thioridazineDrug Metab Dispos200634347147616272405
   PubMed Web of Science ®Google Scholar
• GrossmanISullivanPFWalleyNGenetic determinants of variable metabolism have little impact on the clinical use of leading antipsychotics in the CATIE studyGenet Med2008101072072918813134
   PubMed Web of Science ®Google Scholar
• de LeonJSusceMTPanRMKochWHWedlundPJPolymorphic variations in GSTM1, GSTT1, PgP, CYP2D6, CYP3A5, and dopamine D2 and D3 receptors and their association with tardive dyskinesia in severe mental illnessJ Clin Psychopharmacol200525544845616160620
   PubMed Web of Science ®Google Scholar
• OhmoriOSuzukiTKojimaHTardive dyskinesia and debrisoquine 4-hydroxylase (CYP2D6) genotype in Japanese schizophrenicsSchizophr Res19983221071139713906
   PubMed Web of Science ®Google Scholar
• CrescentiAMasSGassoPParelladaEBernardoMLafuenteACyp2d6*3, *4, *5 and *6 polymorphisms and antipsychotic-induced extrapyramidal side-effects in patients receiving antipsychotic therapyClin Exp Pharmacol Physiol200835780781118346175
   PubMed Web of Science ®Google Scholar
• EllingrodVLSchultzSKArndtSAbnormal movements and tardive dyskinesia in smokers and nonsmokers with schizophrenia genotyped for cytochrome P450 2D6Pharmacotherapy200222111416141912432967
   PubMed Web of Science ®Google Scholar
• KoolaMMTsapakisEMWrightPAssociation of tardive dyskinesia with variation in CYP2D6: Is there a role for active metabolites?J Psychopharmacol34201428766567024595968
   PubMed Web of Science ®Google Scholar
• LiouYJWangYCBaiYMCytochrome P-450 2D6*10 C188T polymorphism is associated with antipsychotic-induced persistent tardive dyskinesia in Chinese schizophrenic patientsNeuropsychobiology200449416717315118351
   PubMed Web of Science ®Google Scholar
• NikoloffDShimJCFairchildMAssociation between CYP2D6 genotype and tardive dyskinesia in Korean schizophrenicsPharmacogenomics J20022640040712629505
   PubMedGoogle Scholar
• FuYFanCHDengHHAssociation of CYP2D6 and CYP1A2 gene polymorphism with tardive dyskinesia in Chinese schizophrenic patientsActa Pharmacol Sin200627332833216490169
   PubMed Web of Science ®Google Scholar
• AndreassenOAMacEwanTGulbrandsenAKMcCreadieRGSteenVMNon-functional CYP2D6 alleles and risk for neuroleptic-induced movement disorders in schizophrenic patientsPsychopharmacology (Berl)199713121741799201806
   PubMed Web of Science ®Google Scholar
• ScordoMGSpinaERomeoPCYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patientsEur J Clin Pharmacol2000569–1067968311214775
   PubMed Web of Science ®Google Scholar
• LohmannPLBagliMKraussHCYP2D6 polymorphism and tardive dyskinesia in schizophrenic patientsPharmacopsychiatry2003362737812734765
   PubMed Web of Science ®Google Scholar
• de LeonJSusceMTPanRMFairchildMKochWHWedlundPJThe CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuationJ Clin Psychiatry2005661152715669884
   PubMed Web of Science ®Google Scholar
• TiwariAKDeshpandeSNRaoARGenetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: III. Lack of association of CYP3A4 and CYP2D6 gene polymorphismsSchizophr Res2005751212615820320
   PubMed Web of Science ®Google Scholar
• TsaiHTCaroffSNMillerDDA candidate gene study of Tardive dyskinesia in the CATIE schizophrenia trialAm J Med Genet B Neuropsychiatr Genet2010153B133634019475583
   PubMed Web of Science ®Google Scholar
• MurrayMRole of CYP pharmacogenetics and drug-drug interactions in the efficacy and safety of atypical and other antipsychotic agentsJ Pharm Pharmacol200658787188516805946
   PubMed Web of Science ®Google Scholar
• ChongSATanECTanCHMythilySmoking and tardive dyskinesia: lack of involvement of the CYP1A2 geneJ Psychiatry Neurosci200328318518912790158
   PubMed Web of Science ®Google Scholar
• BokeOGunesSKaraNAssociation of serotonin 2A receptor and lack of association of CYP1A2 gene polymorphism with tardive dyskinesia in a Turkish populationDNA Cell Biol200726852753117688403
   PubMed Web of Science ®Google Scholar
• SchulzeTGSchumacherJMüllerDJLack of association between a functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene and tardive dyskinesia in schizophreniaAm J Med Genet2001105649850111496364
   PubMed Web of Science ®Google Scholar
• RavynDRavynVLowneyRNasrallahHACYP450 pharmacogenetic treatment strategies for antipsychotics: a review of the evidenceSchizophr Res20131491–311423870808
   PubMed Web of Science ®Google Scholar
• McGrawJWallerDCytochrome P450 variations in different ethnic populationsExpert Opin Drug Metab Toxicol20128337138222288606
   PubMed Web of Science ®Google Scholar
• MeshulCKCaseyDERegional, reversible ultrastructural changes in rat brain with chronic neuroleptic treatmentBrain Res198948923383462568156
   PubMed Web of Science ®Google Scholar
• CaseyDEGerlachJBjorndalNLevodopa and receptor sensitivity modification in tardive dyskinesiaPsychopharmacology (Berl)198278189926128757
   PubMed Web of Science ®Google Scholar
• SilvestriSSeemanMVNegreteJCIncreased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET studyPsychopharmacology (Berl)2000152217418011057521
   PubMed Web of Science ®Google Scholar
• BlinJBaronJCCambonHStriatal dopamine D2 receptors in tardive dyskinesia: PET studyJ Neurol Neurosurg Psychiatry19895211124812522574230
   PubMed Web of Science ®Google Scholar
• SrivastavaVVarmaPGPrasadSGenetic susceptibility to tardive dyskinesia among schizophrenia subjects: IV. Role of dopaminergic pathway gene polymorphismsPharmacogenet Genomics200616211111716424823
   PubMed Web of Science ®Google Scholar
• LiouYJLaiICLiaoDLThe human dopamine receptor D2 (DRD2) gene is associated with tardive dyskinesia in patients with schizophreniaSchizophr Res2006861–332332516769201
   PubMed Web of Science ®Google Scholar
• ZaiCCDe LucaVHwangRWMeta-analysis of two dopamine D2 receptor gene polymorphisms with tardive dyskinesia in schizophrenia patientsMol Psychiatry200712979479517767146
   PubMed Web of Science ®Google Scholar
• LattuadaECavallaroRSerrettiALorenziCSmeraldiETardive dyskinesia and DRD2, DRD3, DRD4, 5-HT2A variants in schizophrenia: an association study with repeated assessmentInt J Neuropsychopharmacol20047448949315383158
   PubMed Web of Science ®Google Scholar
• ChongSATanECTanCHMythilyChanYHPolymorphisms of dopamine receptors and tardive dyskinesia among Chinese patients with schizophreniaAm J Med Genet B Neuropsychiatr Genet2003116B1515412497614
   PubMed Web of Science ®Google Scholar
• HoriHOhmoriOShinkaiTKojimaHNakamuraJAssociation between three functional polymorphisms of dopamine D2 receptor gene and tardive dyskinesia in schizophreniaAm J Med Genet2001105877477811803529
   PubMed Web of Science ®Google Scholar
• ParkYMKangSGChoiJENo Evidence for an Association between Dopamine D2 Receptor Polymorphisms and Tardive Dyskinesia in Korean Schizophrenia PatientsPsychiatry Investig2011814954
   Web of Science ®Google Scholar
• ZaiCCHwangRWDe LucaVAssociation study of tardive dyskinesia and twelve DRD2 polymorphisms in schizophrenia patientsInt J Neuropsychopharmacol200710563965116959057
   PubMed Web of Science ®Google Scholar
• WooSIKimJWRhaEAssociation of the Ser9Gly polymorphism in the dopamine D3 receptor gene with tardive dyskinesia in Korean schizophrenicsPsychiatry Clin Neurosci200256446947412109967
   PubMed Web of Science ®Google Scholar
• LiaoDLYehYCChenHMChenHHongCJTsaiSJAssociation between the Ser9Gly polymorphism of the dopamine D3 receptor gene and tardive dyskinesia in Chinese schizophrenic patientsNeuropsychobiology2001442959811490179
   PubMed Web of Science ®Google Scholar
• Al HadithyAFIvanovaSAPechlivanoglouPTardive dyskinesia and DRD3, HTR2A and HTR2C gene polymorphisms in Russian psychiatric inpatients from SiberiaProg Neuropsychopharmacol Biol Psychiatry200933347548119439249
   PubMed Web of Science ®Google Scholar
• TsaiHTNorthKEWestSLPooleCThe DRD3 rs6280 polymorphism and prevalence of tardive dyskinesia: a meta-analysisAm J Med Genet B Neuropsychiatr Genet2010153B1576619358223
   PubMed Web of Science ®Google Scholar
• LererBSegmanRHFangerauHPharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphismNeuropsychopharmacology200227110511912062911
   PubMed Web of Science ®Google Scholar
• UtsunomiyaKShinkaiTSakataSGenetic association between the dopamine D3 receptor gene polymorphism (Ser9Gly) and tardive dyskinesia in patients with schizophrenia: a reevaluation in East Asian populationsNeurosci Lett20125071525622172931
   PubMed Web of Science ®Google Scholar
• WilffertBAl HadithyAFSingVJThe role of dopamine D3, 5-HT2A and 5-HT2C receptor variants as pharmacogenetic determinants in tardive dyskinesia in African-Caribbean patients under chronic antipsychotic treatment: Curacao extrapyramidal syndromes study IXJ Psychopharmacol200923665265918562401
   PubMed Web of Science ®Google Scholar
• ShamyMCZaiCBasileVSKennedyJLMüllerDJMasellisMEthical and Policy Considerations in the Application of Pharmacogenomic Testing for Tardive Dyskinesia: Case Study of the Dopamine D3 ReceptorCurr Pharmacogenomics Person Med2011929410122282718
   PubMedGoogle Scholar
• ZaiCCTiwariAKBasileVAssociation study of tardive dyskinesia and five DRD4 polymorphisms in schizophrenia patientsPharmacogenomics J20099316817419238168
   PubMed Web of Science ®Google Scholar
• RietschelMKraussHMüllerDJDopamine D3 receptor variant and tardive dyskinesiaEur Arch Psychiatry Clin Neurosci20002501313510738862
   PubMed Web of Science ®Google Scholar
• SegmanRHGoltserTHeresco-LevyUAssociation of dopaminergic and serotonergic genes with tardive dyskinesia in patients with chronic schizophreniaPharmacogenomics J20033527728314583797
   PubMed Web of Science ®Google Scholar
• LeeHJKangSGChoiJENo association between dopamine D4 receptor gene -521 C/T polymorphism and tardive dyskinesia in schizophreniaNeuropsychobiology2007551475117556853
   PubMed Web of Science ®Google Scholar
• YoderKKHutchinsGDMorrisEDBrashearAWangCShekharADopamine transporter density in schizophrenic subjects with and without tardive dyskinesiaSchizophr Res2004712–337137515474908
   PubMed Web of Science ®Google Scholar
• GuillinODiazJCarrollPGriffonNSchwartzJCSokoloffPBDNF controls dopamine D3 receptor expression and triggers behavioural sensitizationNature20014116833868911333982
   PubMed Web of Science ®Google Scholar
• KnüselBWinslowJWRosenthalAPromotion of central cholinergic and dopaminergic neuron differentiation by brain-derived neurotrophic factor but not neurotrophin 3Proc Natl Acad Sci U S A19918839619651992488
   PubMed Web of Science ®Google Scholar
• BeckKDKnüselBHeftiFThe nature of the trophic action of brain-derived neurotrophic factor, des(1–3)-insulin-like growth factor-1, and basic fibroblast growth factor on mesencephalic dopaminergic neurons developing in cultureNeuroscience19935248558668095710
   PubMed Web of Science ®Google Scholar
• LiouYJLiaoDLChenJYAssociation analysis of the dopamine D3 receptor gene ser9gly and brain-derived neurotrophic factor gene val66met polymorphisms with antipsychotic-induced persistent tardive dyskinesia and clinical expression in Chinese schizophrenic patientsNeuromolecular Med20045324325115626824
   PubMed Web of Science ®Google Scholar
• ZaiCCTiwariAKDe LucaVGenetic study of BDNF, DRD3, and their interaction in tardive dyskinesiaEur Neuropsychopharmacol200919531732819217756
   PubMed Web of Science ®Google Scholar
• JopeRSRohMSGlycogen synthase kinase-3 (GSK3) in psychiatric diseases and therapeutic interventionsCurr Drug Targets20067111421143417100582
   PubMed Web of Science ®Google Scholar
• ParkSWLeeJGKongBGGenetic association of BDNF val66met and GSK-3beta-50T/C polymorphisms with tardive dyskinesiaPsychiatry Clin Neurosci200963443343919457211
   PubMed Web of Science ®Google Scholar
• LohrJBKuczenskiRNiculescuABOxidative mechanisms and tardive dyskinesiaCNS Drugs2003171476212467492
   PubMed Web of Science ®Google Scholar
• HaradaSTachikawaHKawanishiYGlutathione S-transferase M1 gene deletion may be associated with susceptibility to certain forms of schizophreniaBiochem Biophys Res Commun2001281226727111181039
   PubMed Web of Science ®Google Scholar
• PaeCUYuHSKimJJGlutathione S-transferase M1 polymorphism may contribute to schizophrenia in the Korean populationPsychiatr Genet200414314715015318028
   PubMed Web of Science ®Google Scholar
• Al HadithyAFIvanovaSAPechlivanoglouPMissense polymorphisms in three oxidative-stress enzymes (GSTP1, SOD2, and GPX1) and dyskinesias in Russian psychiatric inpatients from SiberiaHum Psychopharmacol2010251849120041472
   PubMed Web of Science ®Google Scholar
• ShinkaiTDe LucaVHwangRAssociation study between a functional glutathione S-transferase (GSTP1) gene polymorphism (Ile105Val) and tardive dyskinesiaNeurosci Lett2005388211612016039055
   PubMed Web of Science ®Google Scholar
• HuYJDiamondAMRole of glutathione peroxidase 1 in breast cancer: loss of heterozygosity and allelic differences in the response to seleniumCancer Res200363123347335112810669
   PubMed Web of Science ®Google Scholar
• ShinkaiTMüllerDJDe LucaVGenetic association analysis of the glutathione peroxidase (GPX1) gene polymorphism (Pro197Leu) with tardive dyskinesiaPsychiatry Res2006141212312816413612
   PubMed Web of Science ®Google Scholar
• HoriHOhmoriOShinkaiTManganese superoxide dismutase gene polymorphism and schizophrenia: relation to tardive dyskinesiaNeuropsychopharmacology200023217017710882843
   PubMed Web of Science ®Google Scholar
• ZhangZZhangXHouGShaWReynoldsGPThe increased activity of plasma manganese superoxide dismutase in tardive dyskinesia is unrelated to the Ala-9Val polymorphismJ Psychiatr Res200236531732412127599
   PubMed Web of Science ®Google Scholar
• PaeCUKimTSPatkarAAManganese superoxide dismutase (MnSOD: Ala-9Val) gene polymorphism may not be associated with schizophrenia and tardive dyskinesiaPsychiatry Res20071531778117582511
   PubMed Web of Science ®Google Scholar
• LiuHWangCChenPHAssociation of the manganese superoxide dismutase gene Ala-9Val polymorphism with clinical phenotypes and tardive dyskinesia in schizophrenic patientsProg Neuropsychopharmacol Biol Psychiatry201034469269620346996
   PubMed Web of Science ®Google Scholar
• LachmanHMPapolosDFSaitoTYuYMSzumlanskiCLWeinshilboumRMHuman catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disordersPharmacogenetics1996632432508807664
   PubMedGoogle Scholar
• HanDLeeJLeeYKeeBMinKJNaCThe association between tardive dyskinesia induced by haloperidol and polymorphisms in the serotonin transporter gene and catecholamine-o-methyltransferase gene in Korean schizophrenic patientsClinical Psychopharmacology and Neuroscience2005311621
   Google Scholar
• HerkenHErdalMEBokeOSavasHATardive dyskinesia is not associated with the polymorphisms of 5-HT2A receptor gene, serotonin transporter gene and catechol-o-methyltransferase geneEur Psychiatry2003182778112711403
   PubMed Web of Science ®Google Scholar
• LaiICWangYCLinCCNegative association between catechol-O-methyltransferase (COMT) gene Val158Met polymorphism and persistent tardive dyskinesia in schizophreniaJ Neural Transm200511281107111315583953
   PubMed Web of Science ®Google Scholar
• MatsumotoCShinkaiTHoriHOhmoriONakamuraJPolymorphisms of dopamine degradation enzyme (COMT and MAO) genes and tardive dyskinesia in patients with schizophreniaPsychiatry Res20041271–21715261699
   PubMed Web of Science ®Google Scholar
• SabolSZHuSHamerDA functional polymorphism in the monoamine oxidase A gene promoterHum Genet199810332732799799080
   PubMed Web of Science ®Google Scholar
• GarpenstrandHEkblomJForslundKRylanderGOrelandLPlatelet monoamine oxidase activity is related to MAOB intron 13 genotypeJ Neural Transm2000107552353011072748
   PubMed Web of Science ®Google Scholar
• GassóPMasSCrescentiALack of association between antipsychotic-induced extrapyramidal symptoms and polymorphisms in dopamine metabolism and transport genesPsychiatry Res20101751–217317519892410
   PubMed Web of Science ®Google Scholar
• NedergaardSBolamJPGreenfieldSAFacilitation of a dendritic calcium conductance by 5-hydroxytryptamine in the substantia nigraNature198833361691741772897080
   PubMed Web of Science ®Google Scholar
• WarrenJTJrPeacockMLRodriguezLCFinkJKAn MspI polymorphism in the hyman serotonin receptor gene (HTR2): detection by DGGE and RFLP analysisHum Mol Genet1993233387684645
   PubMed Web of Science ®Google Scholar
• MeltzerHYAn overview of the mechanism of action of clozapineJ Clin Psychiatry199455Suppl B47527961573
   PubMed Web of Science ®Google Scholar
• SegmanRHHeresco-LevyUFinkelBAssociation between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophreniaMol Psychiatry20016222522911317227
   PubMed Web of Science ®Google Scholar
• BasileVSOzdemirVMasellisMLack of association between serotonin-2A receptor gene (HTR2A) polymorphisms and tardive dyskinesia in schizophreniaMol Psychiatry20016223023411317228
   PubMed Web of Science ®Google Scholar
• LererBSegmanRHTanECCombined analysis of 635 patients confirms an age-related association of the serotonin 2A receptor gene with tardive dyskinesia and specificity for the non-orofacial subtypeInt J Neuropsychopharmacol20058341142515857569
   PubMed Web of Science ®Google Scholar
• TanECChongSAMahendranRDongFTanCHSusceptibility to neuroleptic-induced tardive dyskinesia and the T102C polymorphism in the serotonin type 2A receptorBiol Psychiatry200150214414711526996
   PubMed Web of Science ®Google Scholar
• HsiehCJChenYCLaiMSHongCJChienKLGenetic variability in serotonin receptor and transporter genes may influence risk for tardive dyskinesia in chronic schizophreniaPsychiatry Res2011188117517621055833
   PubMed Web of Science ®Google Scholar
• ReavillCKettleAHollandVRileyGBlackburnTPAttenuation of haloperidol-induced catalepsy by a 5-HT2C receptor antagonistBr J Pharmacol1999126357257410188965
   PubMed Web of Science ®Google Scholar
• Eberle-WangKLuckiIChesseletMFA role for the subthalamic nucleus in 5-HT2C-induced oral dyskinesiaNeuroscience19967211171288730711
   PubMed Web of Science ®Google Scholar
• ZhangZJZhangXBShaWWReynoldsGPAssociation of a polymorphism in the promoter region of the serotonin 5-HT2C receptor gene with tardive dyskinesia in patients with schizophreniaMol Psychiatry20027767067112192608
   PubMed Web of Science ®Google Scholar
• SegmanRHHeresco-LevyUFinkelBAssociation between the serotonin 2C receptor gene and tardive dyskinesia in chronic schizophrenia: additive contribution of 5-HT2Cser and DRD3gly alleles to susceptibilityPsychopharmacology (Berl)2000152440841311140333
   PubMed Web of Science ®Google Scholar
• SegmanRHLererBAge and the relationship of dopamine D3, serotonin 2C and serotonin 2A receptor genes to abnormal involuntary movements in chronic schizophreniaMol Psychiatry20027213713911840306
   PubMed Web of Science ®Google Scholar
• RothBLCraigoSCChoudharyMSBinding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptorsJ Pharmacol Exp Ther19942683140314107908055
   PubMed Web of Science ®Google Scholar
• OhmoriOShinkaiTHoriHNakamuraJGenetic association analysis of 5-HT(6) receptor gene polymorphism (267C/T) with tardive dyskinesiaPsychiatry Res200211029710212057822
   PubMed Web of Science ®Google Scholar
• ChongSATanECTanCHMahendrenRTayAHChuaHCTardive dyskinesia is not associated with the serotonin gene polymorphism (5-HTTLPR) in ChineseAm J Med Genet200096671271511121166
   PubMed Web of Science ®Google Scholar
• NaiduPSKulkarniSKExcitatory mechanisms in neuroleptic-induced vacuous chewing movements (VCMs): possible involvement of calcium and nitric oxideBehav Pharmacol200112320921611485057
   PubMed Web of Science ®Google Scholar
• ShinkaiTOhmoriOMatsumotoCHoriHKennedyJLNakamuraJGenetic association analysis of neuronal nitric oxide synthase gene polymorphism with tardive dyskinesiaNeuromolecular Med20045216317015075442
   PubMed Web of Science ®Google Scholar
• WangYCLiouYJLiaoDLAssociation analysis of a neural nitric oxide synthase gene polymorphism and antipsychotics-induced tardive dyskinesia in Chinese schizophrenic patientsJ Neural Transm2004111562362915088155
   PubMed Web of Science ®Google Scholar
• ThelmaBKTiwariAKDeshpandeSNLererBNimgaonkarVLGenetic susceptibility to Tardive Dyskinesia in chronic schizophrenia subjects: role of oxidative stress pathway genesSchizophr Res2007921–327827917317105
   PubMed Web of Science ®Google Scholar
• PaeCUYuHSKimJJQuinone oxidoreductase (NQO1) gene polymorphism (609C/T) may be associated with tardive dyskinesia, but not with the development of schizophreniaInt J Neuropsychopharmacol20047449550015151706
   PubMed Web of Science ®Google Scholar
• LeeHJKangSGChoiJENo Evidence for Association between Tyrosine Hydroxylase Gene Val81Met Polymorphism and Susceptibility to Tardive Dyskinesia in SchizophreniaPsychiatry Investig200962108111
   Web of Science ®Google Scholar
• LiouYJWangYCChenJYAssociation analysis of polymorphisms in the N-methyl-D-aspartate (NMDA) receptor subunit 2B (GRIN2B) gene and tardive dyskinesia in schizophreniaPsychiatry Res2007153327127517669510
   PubMed Web of Science ®Google Scholar
• LeeHJKangSGPaikJWNo evidence for an association between G protein beta3 subunit gene C825T polymorphism and tardive dyskinesia in schizophreniaHum Psychopharmacol200722850150417726725
   PubMed Web of Science ®Google Scholar
• Fernández-RuizJThe endocannabinoid system as a target for the treatment of motor dysfunctionBr J Pharmacol200915671029104019220290
   PubMed Web of Science ®Google Scholar
• IpsenMZhangYDragstedNHanCMulvanyMJThe antipsychotic drug sertindole is a specific inhibitor of alpha1A-adrenoceptors in rat mesenteric small arteriesEur J Pharmacol1997336129359384251
   PubMed Web of Science ®Google Scholar
• SvenssonTHAlpha-adrenoceptor modulation hypothesis of antipsychotic atypicalityProg Neuropsychopharmacol Biol Psychiatry20032771145115814642973
   PubMed Web of Science ®Google Scholar
• BeaulieuJMTirottaESotnikovaTDRegulation of Akt signaling by D2 and D3 dopamine receptors in vivoJ Neurosci200727488188517251429
   PubMed Web of Science ®Google Scholar
• KimDChungJAkt: versatile mediator of cell survival and beyondJ Biochem Mol Biol200235110611516248975
   PubMedGoogle Scholar
• ZaiCCRomano-SilvaMAHwangRGenetic study of eight AKT1 gene polymorphisms and their interaction with DRD2 gene polymorphisms in tardive dyskinesiaSchizophr Res20081062–324825218838251
   PubMed Web of Science ®Google Scholar
• BigosKLBiesRRPollockBGGenetic variation in CYP3A43 explains racial difference in clanzapine clearanceMol Physciatry2011166620625
   Google Scholar
• LovlieRDalyAKMatreGEPolymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype a, role for the CYP2D6*35 allele in ultrarapid metabolsim?Pharmacogentics20111114555
   Google Scholar
• Weslind-JohnssonAHermannRHvennemeyerAidentification and characcter of CYP3A4*20, a novel rare CYP3A4 allele without functional activityClin Pharmacol Ther200679433934916580902
   PubMed Web of Science ®Google Scholar
• GaedigkABradforLDMarcuciKAUnique CYP2D6 activity distribution and genotype-phenotype discordance in black AmericansClin Pharmacol Ther2002721768912152006
   PubMed Web of Science ®Google Scholar
• ZhouSFLiuJpChowbayBPolymorphism of human cytochrome P450 enzymes and its clinical impactDrug Metab Rev20094128929519514967
   PubMed Web of Science ®Google Scholar